aluates Reports

$ 0.0

Automative

Global Neurodegenerative Disorder Therapeutics Market Research Report 2025

Published Date: July 2025

Report Code: QYRE-Auto-2I13677

Global Neurodegenerative Disorder Therapeutics Market Research Report 2023

BUY CHAPTERS

Global Neurodegenerative Disorder Therapeutics Market Research Report 2025

Code: QYRE-Auto-2I13677

Report

July 2025

Pages:83

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Biogen

Pfizer Inc

Novartis

Sanofi

Teva Pharmaceutical Industries Ltd

UCB

F Hoffmann La Roche Ltd

H.Lundbeck

Merck KGaA

GlaxoSmithKline PLC

AbbVie

Bristol Myers Squibb Company

Boehringer Ingeiheim International GmbH

Bayer

Eisai Co Ltd

Neurodegenerative Disorder Therapeutics Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Neurodegenerative Disorder Therapeutics Market

The global market for Neurodegenerative Disorder Therapeutics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The goal of therapeutic development for neurodegenerative disorders is to develop drugs that slow down or stop the neurodegenerative process. So-called neuroprotective, or disease-modifying, therapies would not only treat the symptoms but slow the continued loss of neurons in disease.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Neurodegenerative Disorder Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurodegenerative Disorder Therapeutics.

The Neurodegenerative Disorder Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neurodegenerative Disorder Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Neurodegenerative Disorder Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Neurodegenerative Disorder Therapeutics Market Report

Report Metric	Details
Report Name	Neurodegenerative Disorder Therapeutics Market
CAGR	5%
Segment by Type	Immunomodulators Interferons Decarboxylase Inhibitors Dopamine Agonists Others
Segment by Application	Multiple Sclerosis Parkinson'S Disease Alzheimer'S Disease Spinal Muscular Atrophy Huntington Disease Other Neurodegenerative Disorders
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Biogen, Inc., Pfizer, Inc., Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann- La Roche Ltd., H. Lundbeck, Merck KGaA, GlaxoSmithKline PLC, AbbVie Inc., Bristol Myers Squibb Company, Boehringer Ingeiheim International GmbH, Bayer AG, Eisai Co., Ltd
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurodegenerative Disorder Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Neurodegenerative Disorder Therapeutics Market report?

Ans: The main players in the Neurodegenerative Disorder Therapeutics Market are Biogen, Inc., Pfizer, Inc., Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann- La Roche Ltd., H. Lundbeck, Merck KGaA, GlaxoSmithKline PLC, AbbVie Inc., Bristol Myers Squibb Company, Boehringer Ingeiheim International GmbH, Bayer AG, Eisai Co., Ltd

What are the Application segmentation covered in the Neurodegenerative Disorder Therapeutics Market report?

Ans: The Applications covered in the Neurodegenerative Disorder Therapeutics Market report are Multiple Sclerosis, Parkinson'S Disease, Alzheimer'S Disease, Spinal Muscular Atrophy, Huntington Disease, Other Neurodegenerative Disorders

What are the Type segmentation covered in the Neurodegenerative Disorder Therapeutics Market report?

Ans: The Types covered in the Neurodegenerative Disorder Therapeutics Market report are Immunomodulators, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Immunomodulators

1.2.3 Interferons

1.2.4 Decarboxylase Inhibitors

1.2.5 Dopamine Agonists

1.2.6 Others

1.3 Market by Application

1.3.1 Global Neurodegenerative Disorder Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Multiple Sclerosis

1.3.3 Parkinson'S Disease

1.3.4 Alzheimer'S Disease

1.3.5 Spinal Muscular Atrophy

1.3.6 Huntington Disease

1.3.7 Other Neurodegenerative Disorders

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Neurodegenerative Disorder Therapeutics Market Perspective (2020-2031)

2.2 Global Neurodegenerative Disorder Therapeutics Growth Trends by Region

2.2.1 Global Neurodegenerative Disorder Therapeutics Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Neurodegenerative Disorder Therapeutics Historic Market Size by Region (2020-2025)

2.2.3 Neurodegenerative Disorder Therapeutics Forecasted Market Size by Region (2026-2031)

2.3 Neurodegenerative Disorder Therapeutics Market Dynamics

2.3.1 Neurodegenerative Disorder Therapeutics Industry Trends

2.3.2 Neurodegenerative Disorder Therapeutics Market Drivers

2.3.3 Neurodegenerative Disorder Therapeutics Market Challenges

2.3.4 Neurodegenerative Disorder Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Neurodegenerative Disorder Therapeutics Players by Revenue

3.1.1 Global Top Neurodegenerative Disorder Therapeutics Players by Revenue (2020-2025)

3.1.2 Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Players (2020-2025)

3.2 Global Neurodegenerative Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Neurodegenerative Disorder Therapeutics Revenue

3.4 Global Neurodegenerative Disorder Therapeutics Market Concentration Ratio

3.4.1 Global Neurodegenerative Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Disorder Therapeutics Revenue in 2024

3.5 Global Key Players of Neurodegenerative Disorder Therapeutics Head office and Area Served

3.6 Global Key Players of Neurodegenerative Disorder Therapeutics, Product and Application

3.7 Global Key Players of Neurodegenerative Disorder Therapeutics, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Neurodegenerative Disorder Therapeutics Breakdown Data by Type

4.1 Global Neurodegenerative Disorder Therapeutics Historic Market Size by Type (2020-2025)

4.2 Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Type (2026-2031)

5 Neurodegenerative Disorder Therapeutics Breakdown Data by Application

5.1 Global Neurodegenerative Disorder Therapeutics Historic Market Size by Application (2020-2025)

5.2 Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Neurodegenerative Disorder Therapeutics Market Size (2020-2031)

6.2 North America Neurodegenerative Disorder Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Neurodegenerative Disorder Therapeutics Market Size by Country (2020-2025)

6.4 North America Neurodegenerative Disorder Therapeutics Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Neurodegenerative Disorder Therapeutics Market Size (2020-2031)

7.2 Europe Neurodegenerative Disorder Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2020-2025)

7.4 Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size (2020-2031)

8.2 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2020-2025)

8.4 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Neurodegenerative Disorder Therapeutics Market Size (2020-2031)

9.2 Latin America Neurodegenerative Disorder Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2020-2025)

9.4 Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size (2020-2031)

10.2 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Country (2020-2025)

10.4 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Biogen, Inc.

11.1.1 Biogen, Inc. Company Details

11.1.2 Biogen, Inc. Business Overview

11.1.3 Biogen, Inc. Neurodegenerative Disorder Therapeutics Introduction

11.1.4 Biogen, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025)

11.1.5 Biogen, Inc. Recent Development

11.2 Pfizer, Inc.

11.2.1 Pfizer, Inc. Company Details

11.2.2 Pfizer, Inc. Business Overview

11.2.3 Pfizer, Inc. Neurodegenerative Disorder Therapeutics Introduction

11.2.4 Pfizer, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025)

11.2.5 Pfizer, Inc. Recent Development

11.3 Novartis AG

11.3.1 Novartis AG Company Details

11.3.2 Novartis AG Business Overview

11.3.3 Novartis AG Neurodegenerative Disorder Therapeutics Introduction

11.3.4 Novartis AG Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025)

11.3.5 Novartis AG Recent Development

11.4 Sanofi S.A.

11.4.1 Sanofi S.A. Company Details

11.4.2 Sanofi S.A. Business Overview

11.4.3 Sanofi S.A. Neurodegenerative Disorder Therapeutics Introduction

11.4.4 Sanofi S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025)

11.4.5 Sanofi S.A. Recent Development

11.5 Teva Pharmaceutical Industries Ltd.

11.5.1 Teva Pharmaceutical Industries Ltd. Company Details

11.5.2 Teva Pharmaceutical Industries Ltd. Business Overview

11.5.3 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Introduction

11.5.4 Teva Pharmaceutical Industries Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025)

11.5.5 Teva Pharmaceutical Industries Ltd. Recent Development

11.6 UCB S.A.

11.6.1 UCB S.A. Company Details

11.6.2 UCB S.A. Business Overview

11.6.3 UCB S.A. Neurodegenerative Disorder Therapeutics Introduction

11.6.4 UCB S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025)

11.6.5 UCB S.A. Recent Development

11.7 F. Hoffmann- La Roche Ltd.

11.7.1 F. Hoffmann- La Roche Ltd. Company Details

11.7.2 F. Hoffmann- La Roche Ltd. Business Overview

11.7.3 F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Introduction

11.7.4 F. Hoffmann- La Roche Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025)

11.7.5 F. Hoffmann- La Roche Ltd. Recent Development

11.8 H. Lundbeck

11.8.1 H. Lundbeck Company Details

11.8.2 H. Lundbeck Business Overview

11.8.3 H. Lundbeck Neurodegenerative Disorder Therapeutics Introduction

11.8.4 H. Lundbeck Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025)

11.8.5 H. Lundbeck Recent Development

11.9 Merck KGaA

11.9.1 Merck KGaA Company Details

11.9.2 Merck KGaA Business Overview

11.9.3 Merck KGaA Neurodegenerative Disorder Therapeutics Introduction

11.9.4 Merck KGaA Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025)

11.9.5 Merck KGaA Recent Development

11.10 GlaxoSmithKline PLC

11.10.1 GlaxoSmithKline PLC Company Details

11.10.2 GlaxoSmithKline PLC Business Overview

11.10.3 GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Introduction

11.10.4 GlaxoSmithKline PLC Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025)

11.10.5 GlaxoSmithKline PLC Recent Development

11.11 AbbVie Inc.

11.11.1 AbbVie Inc. Company Details

11.11.2 AbbVie Inc. Business Overview

11.11.3 AbbVie Inc. Neurodegenerative Disorder Therapeutics Introduction

11.11.4 AbbVie Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025)

11.11.5 AbbVie Inc. Recent Development

11.12 Bristol Myers Squibb Company

11.12.1 Bristol Myers Squibb Company Company Details

11.12.2 Bristol Myers Squibb Company Business Overview

11.12.3 Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Introduction

11.12.4 Bristol Myers Squibb Company Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025)

11.12.5 Bristol Myers Squibb Company Recent Development

11.13 Boehringer Ingeiheim International GmbH

11.13.1 Boehringer Ingeiheim International GmbH Company Details

11.13.2 Boehringer Ingeiheim International GmbH Business Overview

11.13.3 Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Introduction

11.13.4 Boehringer Ingeiheim International GmbH Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025)

11.13.5 Boehringer Ingeiheim International GmbH Recent Development

11.14 Bayer AG

11.14.1 Bayer AG Company Details

11.14.2 Bayer AG Business Overview

11.14.3 Bayer AG Neurodegenerative Disorder Therapeutics Introduction

11.14.4 Bayer AG Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025)

11.14.5 Bayer AG Recent Development

11.15 Eisai Co., Ltd

11.15.1 Eisai Co., Ltd Company Details

11.15.2 Eisai Co., Ltd Business Overview

11.15.3 Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Introduction

11.15.4 Eisai Co., Ltd Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025)

11.15.5 Eisai Co., Ltd Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Biogen

Pfizer Inc

Novartis

Sanofi

Teva Pharmaceutical Industries Ltd

UCB

F Hoffmann La Roche Ltd

H.Lundbeck

Merck KGaA

GlaxoSmithKline PLC

AbbVie

Bristol Myers Squibb Company

Boehringer Ingeiheim International GmbH

Bayer

Eisai Co Ltd

List of Tables

Table 1. Global Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Immunomodulators

Table 3. Key Players of Interferons

Table 4. Key Players of Decarboxylase Inhibitors

Table 5. Key Players of Dopamine Agonists

Table 6. Key Players of Others

Table 7. Global Neurodegenerative Disorder Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Neurodegenerative Disorder Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 9. Global Neurodegenerative Disorder Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 10. Global Neurodegenerative Disorder Therapeutics Market Share by Region (2020-2025)

Table 11. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 12. Global Neurodegenerative Disorder Therapeutics Market Share by Region (2026-2031)

Table 13. Neurodegenerative Disorder Therapeutics Market Trends

Table 14. Neurodegenerative Disorder Therapeutics Market Drivers

Table 15. Neurodegenerative Disorder Therapeutics Market Challenges

Table 16. Neurodegenerative Disorder Therapeutics Market Restraints

Table 17. Global Neurodegenerative Disorder Therapeutics Revenue by Players (2020-2025) & (US$ Million)

Table 18. Global Neurodegenerative Disorder Therapeutics Market Share by Players (2020-2025)

Table 19. Global Top Neurodegenerative Disorder Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disorder Therapeutics as of 2024)

Table 20. Ranking of Global Top Neurodegenerative Disorder Therapeutics Companies by Revenue (US$ Million) in 2024

Table 21. Global 5 Largest Players Market Share by Neurodegenerative Disorder Therapeutics Revenue (CR5 and HHI) & (2020-2025)

Table 22. Global Key Players of Neurodegenerative Disorder Therapeutics, Headquarters and Area Served

Table 23. Global Key Players of Neurodegenerative Disorder Therapeutics, Product and Application

Table 24. Global Key Players of Neurodegenerative Disorder Therapeutics, Date of Enter into This Industry

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Neurodegenerative Disorder Therapeutics Market Size by Type (2020-2025) & (US$ Million)

Table 27. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Type (2020-2025)

Table 28. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 29. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Type (2026-2031)

Table 30. Global Neurodegenerative Disorder Therapeutics Market Size by Application (2020-2025) & (US$ Million)

Table 31. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Application (2020-2025)

Table 32. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 33. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Application (2026-2031)

Table 34. North America Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. North America Neurodegenerative Disorder Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 36. North America Neurodegenerative Disorder Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 37. Europe Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 38. Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 39. Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 40. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 41. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 42. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2026-2031) & (US$ Million)

Table 43. Latin America Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 45. Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 46. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 47. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 48. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 49. Biogen, Inc. Company Details

Table 50. Biogen, Inc. Business Overview

Table 51. Biogen, Inc. Neurodegenerative Disorder Therapeutics Product

Table 52. Biogen, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 53. Biogen, Inc. Recent Development

Table 54. Pfizer, Inc. Company Details

Table 55. Pfizer, Inc. Business Overview

Table 56. Pfizer, Inc. Neurodegenerative Disorder Therapeutics Product

Table 57. Pfizer, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 58. Pfizer, Inc. Recent Development

Table 59. Novartis AG Company Details

Table 60. Novartis AG Business Overview

Table 61. Novartis AG Neurodegenerative Disorder Therapeutics Product

Table 62. Novartis AG Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 63. Novartis AG Recent Development

Table 64. Sanofi S.A. Company Details

Table 65. Sanofi S.A. Business Overview

Table 66. Sanofi S.A. Neurodegenerative Disorder Therapeutics Product

Table 67. Sanofi S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 68. Sanofi S.A. Recent Development

Table 69. Teva Pharmaceutical Industries Ltd. Company Details

Table 70. Teva Pharmaceutical Industries Ltd. Business Overview

Table 71. Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Product

Table 72. Teva Pharmaceutical Industries Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 73. Teva Pharmaceutical Industries Ltd. Recent Development

Table 74. UCB S.A. Company Details

Table 75. UCB S.A. Business Overview

Table 76. UCB S.A. Neurodegenerative Disorder Therapeutics Product

Table 77. UCB S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 78. UCB S.A. Recent Development

Table 79. F. Hoffmann- La Roche Ltd. Company Details

Table 80. F. Hoffmann- La Roche Ltd. Business Overview

Table 81. F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Product

Table 82. F. Hoffmann- La Roche Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 83. F. Hoffmann- La Roche Ltd. Recent Development

Table 84. H. Lundbeck Company Details

Table 85. H. Lundbeck Business Overview

Table 86. H. Lundbeck Neurodegenerative Disorder Therapeutics Product

Table 87. H. Lundbeck Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 88. H. Lundbeck Recent Development

Table 89. Merck KGaA Company Details

Table 90. Merck KGaA Business Overview

Table 91. Merck KGaA Neurodegenerative Disorder Therapeutics Product

Table 92. Merck KGaA Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 93. Merck KGaA Recent Development

Table 94. GlaxoSmithKline PLC Company Details

Table 95. GlaxoSmithKline PLC Business Overview

Table 96. GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Product

Table 97. GlaxoSmithKline PLC Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 98. GlaxoSmithKline PLC Recent Development

Table 99. AbbVie Inc. Company Details

Table 100. AbbVie Inc. Business Overview

Table 101. AbbVie Inc. Neurodegenerative Disorder Therapeutics Product

Table 102. AbbVie Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 103. AbbVie Inc. Recent Development

Table 104. Bristol Myers Squibb Company Company Details

Table 105. Bristol Myers Squibb Company Business Overview

Table 106. Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Product

Table 107. Bristol Myers Squibb Company Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 108. Bristol Myers Squibb Company Recent Development

Table 109. Boehringer Ingeiheim International GmbH Company Details

Table 110. Boehringer Ingeiheim International GmbH Business Overview

Table 111. Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Product

Table 112. Boehringer Ingeiheim International GmbH Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 113. Boehringer Ingeiheim International GmbH Recent Development

Table 114. Bayer AG Company Details

Table 115. Bayer AG Business Overview

Table 116. Bayer AG Neurodegenerative Disorder Therapeutics Product

Table 117. Bayer AG Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 118. Bayer AG Recent Development

Table 119. Eisai Co., Ltd Company Details

Table 120. Eisai Co., Ltd Business Overview

Table 121. Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Product

Table 122. Eisai Co., Ltd Revenue in Neurodegenerative Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 123. Eisai Co., Ltd Recent Development

Table 124. Research Programs/Design for This Report

Table 125. Key Data Information from Secondary Sources

Table 126. Key Data Information from Primary Sources

Table 127. Authors List of This Report

List of Figures

Figure 1. Neurodegenerative Disorder Therapeutics Picture

Figure 2. Global Neurodegenerative Disorder Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Neurodegenerative Disorder Therapeutics Market Share by Type: 2024 VS 2031

Figure 4. Immunomodulators Features

Figure 5. Interferons Features

Figure 6. Decarboxylase Inhibitors Features

Figure 7. Dopamine Agonists Features

Figure 8. Others Features

Figure 9. Global Neurodegenerative Disorder Therapeutics Market Size by Application (2020-2031) & (US$ Million)

Figure 10. Global Neurodegenerative Disorder Therapeutics Market Share by Application: 2024 VS 2031

Figure 11. Multiple Sclerosis Case Studies

Figure 12. Parkinson'S Disease Case Studies

Figure 13. Alzheimer'S Disease Case Studies

Figure 14. Spinal Muscular Atrophy Case Studies

Figure 15. Huntington Disease Case Studies

Figure 16. Other Neurodegenerative Disorders Case Studies

Figure 17. Neurodegenerative Disorder Therapeutics Report Years Considered

Figure 18. Global Neurodegenerative Disorder Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 19. Global Neurodegenerative Disorder Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 20. Global Neurodegenerative Disorder Therapeutics Market Share by Region: 2024 VS 2031

Figure 21. Global Neurodegenerative Disorder Therapeutics Market Share by Players in 2024

Figure 22. Global Top Neurodegenerative Disorder Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disorder Therapeutics as of 2024)

Figure 23. The Top 10 and 5 Players Market Share by Neurodegenerative Disorder Therapeutics Revenue in 2024

Figure 24. North America Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. North America Neurodegenerative Disorder Therapeutics Market Share by Country (2020-2031)

Figure 26. United States Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Canada Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Europe Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Europe Neurodegenerative Disorder Therapeutics Market Share by Country (2020-2031)

Figure 30. Germany Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. France Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. U.K. Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Italy Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Russia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Nordic Countries Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Share by Region (2020-2031)

Figure 38. China Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Japan Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. South Korea Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Southeast Asia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. India Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Australia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Latin America Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Latin America Neurodegenerative Disorder Therapeutics Market Share by Country (2020-2031)

Figure 46. Mexico Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Brazil Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Share by Country (2020-2031)

Figure 50. Turkey Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. Saudi Arabia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 52. UAE Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 53. Biogen, Inc. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2020-2025)

Figure 54. Pfizer, Inc. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2020-2025)

Figure 55. Novartis AG Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2020-2025)

Figure 56. Sanofi S.A. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2020-2025)

Figure 57. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2020-2025)

Figure 58. UCB S.A. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2020-2025)

Figure 59. F. Hoffmann- La Roche Ltd. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2020-2025)

Figure 60. H. Lundbeck Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2020-2025)

Figure 61. Merck KGaA Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2020-2025)

Figure 62. GlaxoSmithKline PLC Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2020-2025)

Figure 63. AbbVie Inc. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2020-2025)

Figure 64. Bristol Myers Squibb Company Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2020-2025)

Figure 65. Boehringer Ingeiheim International GmbH Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2020-2025)

Figure 66. Bayer AG Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2020-2025)

Figure 67. Eisai Co., Ltd Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2020-2025)

Figure 68. Bottom-up and Top-down Approaches for This Report

Figure 69. Data Triangulation

Figure 70. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Neurodegenerative Diseases Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Targeted Drugs for Neurodegenerative Diseases Market Research Report 2024

Neurodegenerative Disease Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Neurodegenerative Diseases Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Neuroregeneration Therapy Market Research Report 2024

Global Neurodegenerative Disease Market Insights Forecast to 2030

Global Neurologic Disorder Treatment Drug Market Research Report 2024

Global Degenerative Disc Disease Treatment Market Research Report 2024

Global Targeted Drugs for Parkinson s Disease Market Research Report 2024

Global Deep Brain Stimulation and Service for Parkinson s Disease Market Research Report 2024

Global Parkinson Treatment Drug Market Research Report 2025

Huntingtons Disease Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Retinal Degenerative Disease Treatment Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Amnestic Disorders Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Neuroplasticity Market Research Report 2024

Global Neurological Biomarkers for Alzheimer s and Parkinson s Diseases Market Research Report 2025

Retinal Degenerative Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Targeted Drugs for Huntington s Disease Market Research Report 2024

Global Neuropathic Pain Therapeutics Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions